Bionano Surges Ahead: Q4 2025 Earnings Exceed Expectations
Bionano, a leader in the field of pathology technology, has released its fourth quarter and full year 2025 earnings report, showcasing remarkable progress towards transforming the discipline from analog to digital workflows. CEO Dr. Erik Holmlin highlighted the company's focus on consolidating, automating, and leveraging AI-driven software to revolutionize the field.
In a Q&A session with investors, Bionano's Principal Accounting Officer, Mark Adamchak, presented the company's financial highlights for Q4 2025. Notably, revenue came in at $8 million, down 3% from the previous year's fourth quarter but within the predicted range of $7.8 million-$8 million. Sales of nanochannel array flow cells reached 7,554 units, a 6% decline from the same period in 2024. Despite supply chain delays affecting consumable production, Bionano maintained a healthy backlog of demand heading into 2026.
The company's core revenue for the full year 2025 stood at $28.5 million, down 7% from the previous year but adjusted for discontinued clinical services in 2024. Flow cell sales remained relatively stable at 30,171 units, with a mere 0.4% decrease year-over-year. Furthermore, Bionano exceeded its installation guidance by deploying 32 OGM systems in 2025, compared to an initial projection of 15-20.
In terms of profitability, the company's non-GAAP gross margin for Q4 2025 reached 43%, a notable improvement from 42% in the same quarter last year. The full-year non-GAAP gross margin rose to 47%, marking a significant increase of 1,200 basis points from the previous year, despite lower revenue.
Non-GAAP operating expenses for Q4 2025 came in at $9.7 million, down 9% from the same period in 2024. The full-year non-GAAP operating expense plummeted by 47% to $36.6 million, with a substantial reduction of over $100 million in annualized costs and more than 300 employees since Q2 2023. This transformation is clear evidence of Bionano's successful strategy.
As the company concludes its review for 2025, it boasts an impressive cash reserve of $29.6 million in cash equivalents and available-for-sale securities, including $10.3 million subject to certain restrictions. With this solid foundation, investors can anticipate a promising future for Bionano, with expectations extending into 2027.
